ICON plc | Clinical Research Organisation (CRO) for Drug Development

Webinar: Ensuring pharmacovigilance compliance and robust oversight

8 September, 11AM EST. Register now.

COVID-19: Navigating global market access requirements

Recommendations to maxmise HTA success.

Decentralised and hybrid clinical trials

Considerations in planning and executing.

Pandemic respiratory vaccine clinical trials

Best practices to accelerate operations while the world waits.

Featured Services

Site & Patient Solutions

Transforming recruitment through patient-centric trials and real-world, real-time data.

Biotech

ICON provides full service outsourcing and flexible support for biotech specific needs such as due diligence and asset valuation.

Functional Resourcing

From recruitment of a single clinical professional to managing entire global functions.

Biosimilars

ICON can support product design, development and registration, regulatory support and commercialisation of Biosimilars.

Increasing Site and Patient Compliance

FIRECREST: Digital solutions to increase efficiency in clinical trials by driving site performance.

ICON Insights

05 August 2020

Post pandemic clinical trial strategies: How COVID-19 altered clinical trials forever and what’s next

The COVID-19 pandemic forced the clinical trials industry to accept and accelerate the use of digital health technologies.

30 July 2020

Effective patient recruitment for rare disease research

With 350 million people affected worldwide, rare diseases represent a major unmet medical need. However, the timely recruitment of eligible participants is a challenge for any rare disease clinical trial.

20 July 2020

Encouraging patient participation in real world studies

Real world data offers an alternative approach to observational research, particularly to inform decisions on patient needs and preferences.

01 July 2020

Juvenile Arthritis Awareness Month: This fight is personal

This blog is a condensed version of an ICON employee’s’ personal journey of courage and endurance.

24 June 2020

Enabling clinical development of cell and gene therapies on a global basis

In a recent podcast interview, ICON experts discuss the intricacies of CGT development, the solutions that will enable CGT development on a global basis, and the future of CGT clinical trials.

02 June 2020

Improving access and reimbursement for specialty therapies

Clinical development can better satisfy the evidence needs of payers, and not incorporating the needs of payers early into trial designs risks the need to spend more money later on.

29 May 2020

The differences between the US and EU biosimilar markets

Biosimilar uptake in the US market has, until now, stood in stark contrast to that in the EU, which has led the way in biosimilar approvals and use since 2006.

05 May 2020

How to ensure your trial data and patients remain safe during COVID-19

The COVID-19 pandemic has presented an array of cybersecurity challenges. With no slowing down of the virus’s spread, hackers and other cyber criminals are continuing to seize opportunities to take advantage of vulnerable networks.

29 April 2020

The impact of COVID-19 on pharmacovigilance

COVID-19 is affecting how clinical trials are managed, in terms of patient recruitment, patient care, data collection, analysis and safety reporting.

Services

Sectors

Therapeutics

Innovation

Insights

News & Events

About ICON

Patient Centricity

COVID-19 clinical operations

Advancing digital endpoints

The role of estimands